JAHA:ST段抬高型心肌梗死患者神经肽Y水平与冠状动脉微血管功能、心力衰竭和死亡率的关系

2022-07-04 MedSci原创 MedSci原创

ST段抬高心肌梗死后,外周静脉和冠状静脉窦NPY水平与微血管功能和梗死面积相关。外周静脉NPY水平与随后的心衰发展或死亡率相关,因此它可能是一个有用的预后标志。

对于ST段抬高型急性心肌梗死患者,当前的目标是通过首次经皮冠状动脉介入治疗(PPCI)对梗死相关的心外膜血管进行快速血运重建,以恢复冠状动脉灌注。交感共传递素神经肽Y(NPY)在ST段抬高心肌梗死时释放到冠状动脉窦,并可收缩冠状动脉微血管。

近日,心血管疾病领域权威杂志JAHA上发表了一篇研究文章,研究人员试图明确容易获得和测量的外周静脉NPY水平是否与微血管阻塞、心肌恢复和预后相关。

研究人员对接受首次经皮冠状动脉介入治疗的患者立即测定NPY水平,并与血管造影和心血管磁共振微血管功能指标进行比较。

受试者前瞻性地随访6.4年(四分位差范围为4.1-8.0年)。外周静脉(n=163)与冠状窦(n=68)NPY水平呈显著相关(r=0.92;P<0.001),与多种冠脉及微血管功能和梗死面积的影像学参数(如冠状动脉血流储备、急性心肌水肿、左室射血分数和6个月后钆增强晚期)相关。因此,研究人员在随访期间评估了外周静脉NPY的预后价值,其中34例(20.7%)患者发生心力衰竭或死亡。Kaplan-Meier生存分析显示,高外周静脉NPY水平(经二元递归划分,>21.4pg/mL)与心力衰竭发生率和死亡率增加相关(风险比为3.49[95%CI为1.65-7.4];P<0.001)。在调整了年龄、心血管危险因素和以前的心肌梗死后,这种关联仍然保持不变。

由此可见,ST段抬高心肌梗死后,外周静脉和冠状静脉窦NPY水平与微血管功能和梗死面积相关。外周静脉NPY水平与随后的心衰发展或死亡率相关,因此它可能是一个有用的预后标志。需要进一步的研究来验证这些结果。

原始出处:

Thomas Gibbs.et al.Neuropeptide‐Y Levels in ST‐Segment–Elevation Myocardial Infarction: Relationship With Coronary Microvascular Function, Heart Failure, and Mortality.JAHA.2022.https://www.ahajournals.org/doi/10.1161/JAHA.121.024850

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1268859, encodeId=df0612688592f, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Tue Jul 05 12:06:12 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365444, encodeId=b14c1365444ba, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Tue Jul 05 12:06:12 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423131, encodeId=774a14231311a, content=<a href='/topic/show?id=936c16863b5' target=_blank style='color:#2F92EE;'>#ST段抬高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16863, encryptionId=936c16863b5, topicName=ST段抬高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91d33758978, createdName=gdsun, createdTime=Tue Jul 05 12:06:12 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512026, encodeId=53221512026bd, content=<a href='/topic/show?id=da82895e077' target=_blank style='color:#2F92EE;'>#血管功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89570, encryptionId=da82895e077, topicName=血管功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a8810427189, createdName=1249859em41(暂无昵称), createdTime=Tue Jul 05 12:06:12 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624460, encodeId=d31916244605b, content=<a href='/topic/show?id=f27b16862d9' target=_blank style='color:#2F92EE;'>#ST段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16862, encryptionId=f27b16862d9, topicName=ST段)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=676820671866, createdName=hyf035, createdTime=Tue Jul 05 12:06:12 CST 2022, time=2022-07-05, status=1, ipAttribution=)]
    2022-07-05 zhaohui6731
  2. [GetPortalCommentsPageByObjectIdResponse(id=1268859, encodeId=df0612688592f, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Tue Jul 05 12:06:12 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365444, encodeId=b14c1365444ba, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Tue Jul 05 12:06:12 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423131, encodeId=774a14231311a, content=<a href='/topic/show?id=936c16863b5' target=_blank style='color:#2F92EE;'>#ST段抬高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16863, encryptionId=936c16863b5, topicName=ST段抬高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91d33758978, createdName=gdsun, createdTime=Tue Jul 05 12:06:12 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512026, encodeId=53221512026bd, content=<a href='/topic/show?id=da82895e077' target=_blank style='color:#2F92EE;'>#血管功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89570, encryptionId=da82895e077, topicName=血管功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a8810427189, createdName=1249859em41(暂无昵称), createdTime=Tue Jul 05 12:06:12 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624460, encodeId=d31916244605b, content=<a href='/topic/show?id=f27b16862d9' target=_blank style='color:#2F92EE;'>#ST段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16862, encryptionId=f27b16862d9, topicName=ST段)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=676820671866, createdName=hyf035, createdTime=Tue Jul 05 12:06:12 CST 2022, time=2022-07-05, status=1, ipAttribution=)]
    2022-07-05 mgqwxj
  3. [GetPortalCommentsPageByObjectIdResponse(id=1268859, encodeId=df0612688592f, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Tue Jul 05 12:06:12 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365444, encodeId=b14c1365444ba, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Tue Jul 05 12:06:12 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423131, encodeId=774a14231311a, content=<a href='/topic/show?id=936c16863b5' target=_blank style='color:#2F92EE;'>#ST段抬高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16863, encryptionId=936c16863b5, topicName=ST段抬高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91d33758978, createdName=gdsun, createdTime=Tue Jul 05 12:06:12 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512026, encodeId=53221512026bd, content=<a href='/topic/show?id=da82895e077' target=_blank style='color:#2F92EE;'>#血管功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89570, encryptionId=da82895e077, topicName=血管功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a8810427189, createdName=1249859em41(暂无昵称), createdTime=Tue Jul 05 12:06:12 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624460, encodeId=d31916244605b, content=<a href='/topic/show?id=f27b16862d9' target=_blank style='color:#2F92EE;'>#ST段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16862, encryptionId=f27b16862d9, topicName=ST段)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=676820671866, createdName=hyf035, createdTime=Tue Jul 05 12:06:12 CST 2022, time=2022-07-05, status=1, ipAttribution=)]
    2022-07-05 gdsun
  4. [GetPortalCommentsPageByObjectIdResponse(id=1268859, encodeId=df0612688592f, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Tue Jul 05 12:06:12 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365444, encodeId=b14c1365444ba, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Tue Jul 05 12:06:12 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423131, encodeId=774a14231311a, content=<a href='/topic/show?id=936c16863b5' target=_blank style='color:#2F92EE;'>#ST段抬高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16863, encryptionId=936c16863b5, topicName=ST段抬高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91d33758978, createdName=gdsun, createdTime=Tue Jul 05 12:06:12 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512026, encodeId=53221512026bd, content=<a href='/topic/show?id=da82895e077' target=_blank style='color:#2F92EE;'>#血管功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89570, encryptionId=da82895e077, topicName=血管功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a8810427189, createdName=1249859em41(暂无昵称), createdTime=Tue Jul 05 12:06:12 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624460, encodeId=d31916244605b, content=<a href='/topic/show?id=f27b16862d9' target=_blank style='color:#2F92EE;'>#ST段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16862, encryptionId=f27b16862d9, topicName=ST段)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=676820671866, createdName=hyf035, createdTime=Tue Jul 05 12:06:12 CST 2022, time=2022-07-05, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1268859, encodeId=df0612688592f, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Tue Jul 05 12:06:12 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1365444, encodeId=b14c1365444ba, content=<a href='/topic/show?id=2a2150e76fd' target=_blank style='color:#2F92EE;'>#微血管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50776, encryptionId=2a2150e76fd, topicName=微血管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=669d219, createdName=mgqwxj, createdTime=Tue Jul 05 12:06:12 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423131, encodeId=774a14231311a, content=<a href='/topic/show?id=936c16863b5' target=_blank style='color:#2F92EE;'>#ST段抬高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16863, encryptionId=936c16863b5, topicName=ST段抬高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91d33758978, createdName=gdsun, createdTime=Tue Jul 05 12:06:12 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1512026, encodeId=53221512026bd, content=<a href='/topic/show?id=da82895e077' target=_blank style='color:#2F92EE;'>#血管功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89570, encryptionId=da82895e077, topicName=血管功能)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a8810427189, createdName=1249859em41(暂无昵称), createdTime=Tue Jul 05 12:06:12 CST 2022, time=2022-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624460, encodeId=d31916244605b, content=<a href='/topic/show?id=f27b16862d9' target=_blank style='color:#2F92EE;'>#ST段#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16862, encryptionId=f27b16862d9, topicName=ST段)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=676820671866, createdName=hyf035, createdTime=Tue Jul 05 12:06:12 CST 2022, time=2022-07-05, status=1, ipAttribution=)]
    2022-07-05 hyf035

相关资讯

JACC:高血糖大大推进亚临床心衰的进展!

在亚临床心衰的老年人中,控制不佳的糖尿病与心衰进展的高风险密切相关

Eur Heart J:术后房颤与心力衰竭住院风险的关系

在接受心脏和非心脏手术且无心衰病史的患者中,POAF与心衰住院事件相关。这些结果突出了POAF对患者预后的不良影响,并提示POAF可能是鉴别亚临床心衰患者和心衰高危患者的一个标志。

JAHA:致心律失常右心室心肌病患者不良心力衰竭结局新风险预测模型

该研究已经开发出了新的心律失常性右心室心肌病的风险预测模型,可以识别有终末期心衰事件风险的患者,并可能指导医生评估个体化的心衰风险和优化治疗策略。

Cardiovasc Diabetol:多种营养生物标志物与糖尿病患者心衰结局的相关性

同型半胱氨酸是T2D患者全因死亡的独立危险因素

Cardiovasc Diabetol:糖尿病+心衰患者的进行性右心室功能变化

血糖水平和右心室功能的控制对合并糖尿病的慢性心衰患者的预后至关重要。